Two Sigma Advisers
OTLK icon

Two Sigma Advisers’s Outlook Therapeutics OTLK Stock Holding History

Two Sigma Advisers’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,485
Closed -$53.7K – 2714
2022
Q4 		$53.7K Sell
2,485
-7,340
-75% -$160K ﹤0.01% 2357
2022
Q3 		$240K Sell
9,825
-7,680
-44% -$179K ﹤0.01% 2145
2022
Q2 		$357K Sell
17,505
-9,560
-35% -$275K ﹤0.01% 2064
2022
Q1 		$964K Sell
27,065
-17,485
-39% -$546K ﹤0.01% 1656
2021
Q4 		$1.21M Buy
44,550
+29,055
+188% +$1.04M ﹤0.01% 1462
2021
Q3 		$672K Sell
15,495
-19,295
-55% -$931K ﹤0.01% 1796
2021
Q2 		$1.73M Buy
34,790
+4,625
+15% +$215K ﹤0.01% 1360
2021
Q1 		$1.36M Buy
30,165
+22,985
+320% +$880K ﹤0.01% 1477
2020
Q4 		$187K Sell
7,180
-210
-3% -$4.39K ﹤0.01% 2190
2020
Q3 		$106K Buy
+7,390
New +$165K ﹤0.01% 2268

Other funds holding OTLK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Two Sigma Advisers's OTLK Position: Q1 2023 in Review

Two Sigma Advisers sold out of Outlook Therapeutics (OTLK) in Q1 2023, closing a stake of 2,485 shares — an estimated $53.7K sold.

Two Sigma Advisers first reported a position in OTLK in Q3 2020 and held it in 10 quarters. The position peaked at $1.73M in Q2 2021. 82 funds tracked by Wall St. Rank hold OTLK as of Q1 2023.

  • Two Sigma Advisers reported no remaining Outlook Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Two Sigma Advisers sold 2,485 Outlook Therapeutics shares in Q1 2023, an estimated $53.7K.
  • Two Sigma Advisers first reported a position in Outlook Therapeutics in Q3 2020 and held it in 10 quarters.
  • Two Sigma Advisers's Outlook Therapeutics position peaked at $1.73M in Q2 2021.
  • 82 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2023.

Based on Two Sigma Advisers's 13F filing for Q1 2023, filed 15 May 2023.